Follow the people · Insider
Behrad Derakhshan
Behrad Derakhshan files insider transactions with the SEC as a chief business officer of Edgewise Therapeutics (EWTX). We hold 1 disclosed purchase or sale filed since 19 August 2021, 1 of them in the last 90 days.
- Files forEWTX
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure14 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 17 August 2021 — 12 August 2026Chief Business Officer · Edgewise Therapeutics (EWTX)46 Form 4 lines · source: SEC Form 4
Everything they disclosed
46 entries, newest first — one per disclosure report, one per Form 4 line- was granted 100,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 417 August 2026Stock Option (Right to Buy) · traded 12 August 2026 · filed 17 August 2026
- exercised options over 5,781 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- was granted 100,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Stock Option (Right to Buy) · traded 12 August 2026 · filed 14 August 2026
- exercised options over 7,500 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 2,171 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 304 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 150 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 2,475 shares of Edgewise TherapeuticsSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- exercised options over 5,781 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Restricted Stock Units · traded 12 August 2026 · filed 14 August 2026
- exercised options over 7,500 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Restricted Stock Units · traded 12 August 2026 · filed 14 August 2026
- was granted 50,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2026Restricted Stock Units · traded 12 August 2026 · filed 14 August 2026
- exercised options over 5,781 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2025Restricted Stock Units · traded 12 August 2025 · filed 14 August 2025
- was granted 30,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2025Restricted Stock Units · traded 12 August 2025 · filed 14 August 2025
- was granted 180,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2025Stock Option (Right to Buy) · traded 12 August 2025 · filed 14 August 2025
- exercised options over 5,781 shares of Edgewise TherapeuticsSEC Form 414 August 2025Common Stock · traded 12 August 2025 · filed 14 August 2025
- ▼ sold on the open market 2,491 shares of Edgewise TherapeuticsSEC Form 414 August 2025Common Stock · traded 12 August 2025 · filed 14 August 2025
- exercised options over 5,209 shares of Edgewise Therapeutics (a derivative holding)SEC Form 47 May 2025Restricted Stock Units · traded 1 May 2025 · filed 7 May 2025
- exercised options over 5,209 shares of Edgewise TherapeuticsSEC Form 47 May 2025Common Stock · traded 1 May 2025 · filed 7 May 2025
- ▼ sold on the open market 1,691 shares of Edgewise TherapeuticsSEC Form 47 May 2025Common Stock · traded 2 May 2025 · filed 7 May 2025
- exercised options over 10,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 47 February 2025Stock Option (Right to Buy) · traded 5 February 2025 · filed 7 February 2025
- exercised options over 10,000 shares of Edgewise TherapeuticsSEC Form 47 February 2025Common Stock · traded 5 February 2025 · filed 7 February 2025
- ▼ sold on the open market 10,000 shares of Edgewise TherapeuticsSEC Form 47 February 2025Common Stock · traded 5 February 2025 · filed 7 February 2025
- exercised options over 42,068 shares of Edgewise Therapeutics (a derivative holding)SEC Form 424 September 2024Stock Option (Right to Buy) · traded 20 September 2024 · filed 24 September 2024
- exercised options over 42,068 shares of Edgewise TherapeuticsSEC Form 424 September 2024Common Stock · traded 20 September 2024 · filed 24 September 2024
- ▼ sold on the open market 42,068 shares of Edgewise TherapeuticsSEC Form 424 September 2024Common Stock · traded 20 September 2024 · filed 24 September 2024
- was granted 138,750 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2024Stock Option (Right to Buy) · traded 12 August 2024 · filed 14 August 2024
- was granted 23,125 shares of Edgewise Therapeutics (a derivative holding)SEC Form 414 August 2024Restricted Stock Units · traded 12 August 2024 · filed 14 August 2024
- exercised options over 5,208 shares of Edgewise Therapeutics (a derivative holding)SEC Form 43 May 2024Restricted Stock Units · traded 1 May 2024 · filed 3 May 2024
- exercised options over 5,208 shares of Edgewise TherapeuticsSEC Form 43 May 2024Common Stock · traded 1 May 2024 · filed 3 May 2024
- ▼ sold on the open market 1,718 shares of Edgewise TherapeuticsSEC Form 43 May 2024Common Stock · traded 2 May 2024 · filed 3 May 2024
- exercised options over 600 shares of Edgewise Therapeutics (a derivative holding)SEC Form 49 February 2024Stock Option (Right to Buy) · traded 7 February 2024 · filed 9 February 2024
- exercised options over 4,600 shares of Edgewise Therapeutics (a derivative holding)SEC Form 49 February 2024Stock Option (Right to Buy) · traded 8 February 2024 · filed 9 February 2024
- exercised options over 4,800 shares of Edgewise Therapeutics (a derivative holding)SEC Form 49 February 2024Stock Option (Right to Buy) · traded 9 February 2024 · filed 9 February 2024
- exercised options over 600 shares of Edgewise TherapeuticsSEC Form 49 February 2024Common Stock · traded 7 February 2024 · filed 9 February 2024
- ▼ sold on the open market 600 shares of Edgewise TherapeuticsSEC Form 49 February 2024Common Stock · traded 7 February 2024 · filed 9 February 2024
- exercised options over 4,600 shares of Edgewise TherapeuticsSEC Form 49 February 2024Common Stock · traded 8 February 2024 · filed 9 February 2024
- ▼ sold on the open market 4,600 shares of Edgewise TherapeuticsSEC Form 49 February 2024Common Stock · traded 8 February 2024 · filed 9 February 2024
- exercised options over 4,800 shares of Edgewise TherapeuticsSEC Form 49 February 2024Common Stock · traded 9 February 2024 · filed 9 February 2024
- ▼ sold on the open market 4,800 shares of Edgewise TherapeuticsSEC Form 49 February 2024Common Stock · traded 9 February 2024 · filed 9 February 2024
- was granted 220,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 418 August 2023Stock Option (Right to Buy) · traded 17 August 2023 · filed 18 August 2023
- exercised options over 5,208 shares of Edgewise Therapeutics (a derivative holding)SEC Form 43 May 2023Restricted Stock Units · traded 1 May 2023 · filed 3 May 2023
- exercised options over 5,208 shares of Edgewise TherapeuticsSEC Form 43 May 2023Common Stock · traded 1 May 2023 · filed 3 May 2023
- ▼ sold on the open market 1,747 shares of Edgewise TherapeuticsSEC Form 43 May 2023Common Stock · traded 2 May 2023 · filed 3 May 2023
- was granted 200,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 410 August 2022Stock Option (Right to Buy) · traded 8 August 2022 · filed 10 August 2022
- was granted 15,625 shares of Edgewise Therapeutics (a derivative holding)SEC Form 43 May 2022Restricted Stock Units · traded 1 May 2022 · filed 3 May 2022
- was granted 140,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 419 August 2021Stock Option (Right to Buy) · traded 17 August 2021 · filed 19 August 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.